OLEMA PHARMACEUTICALS, INC. Deferred Tax Liabilities, Gross
OLEMA PHARMACEUTICALS, INC. (OLMA) had Deferred Tax Liabilities, Gross of $495.00 thousand as of 2025-12-31, per its 10-K filed 2026-03-16.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net
us-gaap:DeferredIncomeTaxLiabilities · last filed 2026-03-16
- 2025-12-31: Deferred Tax Liabilities, Gross $495.00K.
- 2024-12-31: Deferred Tax Liabilities, Gross $587.00K.
- 2023-12-31: Deferred Tax Liabilities, Gross $927.00K; Deferred Tax Liabilities, Gross as first filed $281.00K.
- 2022-12-31: Deferred Tax Liabilities, Gross $341.00K.
| Period end | Deferred Tax Liabilities, Gross | Deferred Tax Liabilities, Gross as first filed |
|---|---|---|
| 2025-12-31 | $495.00K 10-K · filed 2026-03-16 | |
| 2024-12-31 | $587.00K 10-K · filed 2026-03-16 | |
| 2023-12-31 | $927.00K 10-K · filed 2025-03-18 | $281.00K 10-K · filed 2024-03-11 |
| 2022-12-31 | $341.00K 10-K · filed 2024-03-11 | |
| 2021-12-31 | $310.00K 10-K · filed 2023-03-09 | |
| 2020-12-31 | $15.00K 10-K · filed 2022-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |